Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The employee equity awards vest over three years and require continued service through each vesting date.

Rhea-AI Summary

Intellia Therapeutics (NTLA) awarded inducement grants covering 44,450 common shares to new employees on October 1, 2026, as an inducement to employment.

The time-based restricted stock units went to eight employees, with one-third vesting annually over three years. Vesting requires continued service through each applicable vesting date. The compensation committee approved the awards under Nasdaq Listing Rule 5635(c)(4). They were granted under the amended 2024 Inducement Plan, outside stockholder-approved equity incentive plans.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.44,450 common shares underlying employee restricted stock units represent potential dilution as the awards vest.

Key Figures

Inducement RSUs: 44,450 shares Recipients: 8 employees Vesting schedule: One-third annually over three years

Inducement RSUs

44,450 shares

Aggregate grant to eight new employees

Recipients

8 employees

New employees receiving inducement grants

Vesting schedule

One-third annually over three years

Time-based restricted stock units

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), crispr gene editing

3 terms

restricted stock units financial

"time-based restricted stock units (“RSUs”) for an aggregate of 44,450 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

crispr gene editing technical

"leveraging CRISPR gene editing and other core technologies"

CRISPR gene editing is a laboratory technique that uses a guided molecular “scissor” to change DNA at specific locations, allowing scientists to add, remove, or correct genetic code. For investors, it matters because it underpins a new class of therapies and biotech products with high upside if they work, but also carries long development timelines, regulatory uncertainty, and technical risks that can create large swings in company value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on October 1, 2026, it awarded inducement grants to eight new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 44,450 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com

This press release was published by a CLEAR® Verified individual.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares do Intellia Therapeutics' October 1, 2026 inducement grants cover?

The grants cover 44,450 shares of common stock in time-based restricted stock units awarded to eight new employees as an inducement to employment.

What is the vesting schedule for Intellia Therapeutics' October 1, 2026 inducement grants?

One-third of the restricted stock units vest annually over three years. Each employee must continue serving as an employee or other service provider to Intellia through the applicable vesting dates.